Skip to Content

KYTH-105 Approval Status

KYTH-105 (setipiprant) is an oral prostaglandin D2 (PGD2) receptor antagonist in development for the treatment of androgenetic alopecia (AGA), or male pattern hair loss.

Development Status and FDA Approval Process for KYTH-105

DateArticle
Sep 22, 2015Kythera Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide